S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Reasons this Tech Giant is Going Back to Highs
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Compelling Reasons to Start Buying Undervalued Amazon
5 Reasons Why Amprius is About to Take Flight 
Get Your Cash Out of U.S. Banks Immediately (Ad)
Stock market today: Asian shares mixed after interest rates-driven sell-off on Wall Street
Analysts Recommend These Mining Stocks Before Metal Prices Rally
Get Your Cash Out of U.S. Banks Immediately (Ad)
5 Sizzling Tech Companies on the Brink of Bullish Reversals
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Reasons this Tech Giant is Going Back to Highs
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Compelling Reasons to Start Buying Undervalued Amazon
5 Reasons Why Amprius is About to Take Flight 
Get Your Cash Out of U.S. Banks Immediately (Ad)
Stock market today: Asian shares mixed after interest rates-driven sell-off on Wall Street
Analysts Recommend These Mining Stocks Before Metal Prices Rally
Get Your Cash Out of U.S. Banks Immediately (Ad)
5 Sizzling Tech Companies on the Brink of Bullish Reversals
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Reasons this Tech Giant is Going Back to Highs
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Compelling Reasons to Start Buying Undervalued Amazon
5 Reasons Why Amprius is About to Take Flight 
Get Your Cash Out of U.S. Banks Immediately (Ad)
Stock market today: Asian shares mixed after interest rates-driven sell-off on Wall Street
Analysts Recommend These Mining Stocks Before Metal Prices Rally
Get Your Cash Out of U.S. Banks Immediately (Ad)
5 Sizzling Tech Companies on the Brink of Bullish Reversals
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Reasons this Tech Giant is Going Back to Highs
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Compelling Reasons to Start Buying Undervalued Amazon
5 Reasons Why Amprius is About to Take Flight 
Get Your Cash Out of U.S. Banks Immediately (Ad)
Stock market today: Asian shares mixed after interest rates-driven sell-off on Wall Street
Analysts Recommend These Mining Stocks Before Metal Prices Rally
Get Your Cash Out of U.S. Banks Immediately (Ad)
5 Sizzling Tech Companies on the Brink of Bullish Reversals
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
NASDAQ:ADAG

Adagene (ADAG) Stock Forecast, Price & News

$1.33
-0.09 (-6.34%)
(As of 09/21/2023 ET)
Compare
Today's Range
$1.30
$1.40
50-Day Range
$1.14
$1.46
52-Week Range
$0.90
$2.10
Volume
12,227 shs
Average Volume
20,539 shs
Market Capitalization
$58.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Adagene MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
275.9% Upside
$5.00 Price Target
Short Interest
Healthy
0.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.65) to ($1.22) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

569th out of 961 stocks

Pharmaceutical Preparations Industry

260th out of 448 stocks


ADAG stock logo

About Adagene (NASDAQ:ADAG) Stock

Adagene Inc., a clinical stage immunotherapy company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.

ADAG Price History

ADAG Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Adagene Announces Updates to its Board of Directors
Expert Ratings for Adagene
Are Medical Stocks Lagging Adagene (ADAG) This Year?
H.C. Wainwright Sticks to Its Buy Rating for Adagene (ADAG)
H.C. Wainwright Keeps Their Buy Rating on Hookipa Pharma (HOOK)
See More Headlines
Receive ADAG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adagene and its competitors with MarketBeat's FREE daily newsletter.

ADAG Company Calendar

Today
9/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADAG
Fax
N/A
Employees
248
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+275.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$9.29 million
Book Value
$1.91 per share

Miscellaneous

Free Float
34,542,000
Market Cap
$58.29 million
Optionable
Not Optionable
Beta
0.18
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Peter P. Luo Ph.D. (Age 57)
    Co- Founder, Chairman, CEO and Pres of R&D
  • Mr. Man Kin Tam M.B.A. (Age 46)
    CFO & Director
  • Dr. Fangyong Du Ph.D. (Age 53)
    CTO & Director
  • Dr. Jc Xu M.D. (Age 58)
    Ph.D., Chief Scientific Officer
  • Ms. Ami Celeste Knoefler
    VP of Investor Relations & Corp. Communications
  • Ms. Ling Zhou
    Head of HR
  • Dr. Qinghai Zhao (Age 62)
    Chief Manufacturing Officer
  • Ms. Yan Li M.B.A. (Age 48)
    Sr. VP of Bioinformatics & Information Technology
  • Ms. Xiaohong She (Age 56)
    Sr. VP & Head of Clinical Operations
  • Dr. Guizhong Liu Ph.D. (Age 52)
    Head of Biology & Pharmacology













ADAG Stock - Frequently Asked Questions

Should I buy or sell Adagene stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adagene in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADAG shares.
View ADAG analyst ratings
or view top-rated stocks.

What is Adagene's stock price forecast for 2023?

2 brokers have issued twelve-month target prices for Adagene's stock. Their ADAG share price forecasts range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next year. This suggests a possible upside of 275.9% from the stock's current price.
View analysts price targets for ADAG
or view top-rated stocks among Wall Street analysts.

How have ADAG shares performed in 2023?

Adagene's stock was trading at $1.3250 at the beginning of the year. Since then, ADAG shares have increased by 0.4% and is now trading at $1.33.
View the best growth stocks for 2023 here
.

When did Adagene IPO?

(ADAG) raised $133 million in an IPO on Tuesday, February 9th 2021. The company issued 7,400,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs (Asia), Morgan Stanley and Jefferies acted as the underwriters for the IPO and China Renaissance was co-manager.

What is Adagene's stock symbol?

Adagene trades on the NASDAQ under the ticker symbol "ADAG."

Who are Adagene's major shareholders?

Adagene's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Strategic Vision Investment Ltd (0.67%) and Renaissance Technologies LLC (0.04%).

How do I buy shares of Adagene?

Shares of ADAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adagene's stock price today?

One share of ADAG stock can currently be purchased for approximately $1.33.

How much money does Adagene make?

Adagene (NASDAQ:ADAG) has a market capitalization of $58.29 million and generates $9.29 million in revenue each year.

How many employees does Adagene have?

The company employs 248 workers across the globe.

How can I contact Adagene?

Adagene's mailing address is 4F BUILDING C14 NO. 218 XINGHU STREET SUZHOU INDUSTRIAL PARK, JIANGSU F4, 215123. The official website for the company is www.adagene.com. The company can be reached via phone at 86-512-8777-3632 or via email at ir@adagene.com.

This page (NASDAQ:ADAG) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -